8-K: Neogen Appoints Bryan Riggsbee as New CFO

Neogen Corporation announced the appointment of Bryan Riggsbee, a seasoned financial leader from bioMérieux and Myriad Genetics, as its new Senior Vice President and Chief Financial Officer, effective November 3, 2025.

Summary

• Neogen Corporation appointed Bryan Riggsbee as Senior Vice President and Chief Financial Officer, effective November 3, 2025.
• Mr. Riggsbee will report directly to Mike Nassif, President and Chief Executive Officer.
• He brings over 25 years of financial leadership experience from the diagnostics and healthcare industries, including roles as CFO at bioMérieux (North America) and Myriad Genetics.
• His compensation package includes an annual base salary of $600,000, eligibility for an annual bonus with a target of 80% of base salary, and an annual equity grant target of $2,000,000.
• Mr. Riggsbee will also receive a one-time sign-on equity grant of $2,250,000 (50% stock options, 50% PSUs) and a $250,000 cash award.
• He is required to relocate to Michigan within 24 months and will receive customary relocation benefits, subject to repayment clauses if employment terminates early.
• Current CFO, David Naemura, is expected to remain with the company until the end of the calendar year to ensure a smooth transition.

Sentiment

Score: 8

Explanation: The appointment of Bryan Riggsbee as CFO is a highly positive development, given his extensive experience and strong track record in relevant industries. His background aligns well with Neogen's strategic goals for growth and operational excellence. The structured transition with the outgoing CFO also adds to the positive sentiment.

Positives

• Appointment of a highly experienced CFO, Bryan Riggsbee, with over 25 years of financial leadership in diagnostics and healthcare.
• Mr. Riggsbee's background includes CFO roles at bioMérieux (North America, $2 billion business) and Myriad Genetics, demonstrating experience in complex global organizations and driving disciplined growth.
• His expertise in expanding company portfolios, partnerships, and international market growth aligns with Neogen's strategic objectives.
• The planned transition period with the outgoing CFO, David Naemura, remaining until year-end, suggests a smooth leadership change.

Risks

• Repayment clauses for the sign-on cash award and relocation benefits if Mr. Riggsbee's employment terminates within one or two years, respectively, could result in financial obligations for him.
• The success of the new CFO in integrating into Neogen's operations and executing strategic initiatives is an inherent risk with any leadership change.

Future Outlook

The filing indicates a strategic focus on strengthening performance and delivering sustainable growth, with the new CFO expected to play a key role in advancing this strategy and execution. The company aims to continue expanding its portfolio and partnerships, and supporting growth into new international markets, leveraging Mr. Riggsbee's past experience.

Management Comments

• "Bryans track record of driving disciplined growth and operational excellence across complex global organizations makes him a strong addition to our leadership team." Mike Nassif, Neogen's CEO and President.
• "His extensive diagnostics background and collaborative approach will be invaluable as we continue executing our strategy to strengthen performance and deliver sustainable growth." Mike Nassif.
• "Neogen's focus on protecting the world's food supply reflects a purpose that deeply resonates with me." Bryan Riggsbee.
• "I look forward to working with this exceptional team to advance our strategy, strengthen execution, and deliver lasting value for our stakeholders." Bryan Riggsbee.

Industry Context

The appointment of a CFO with extensive experience in the diagnostics and healthcare industries, particularly from a $2 billion North American business, suggests Neogen is reinforcing its financial leadership to navigate competitive landscapes and potentially expand its market share in food safety, livestock, and pet health & wellness. This move aligns with a broader industry trend where companies seek seasoned executives to drive growth, optimize operations, and manage complex global financial structures amidst evolving regulatory and market demands.

Comparison to Industry Standards

• Mr. Riggsbee's background as CFO for bioMérieux's $2 billion North American business and nearly a decade as CFO at Myriad Genetics positions him as a highly experienced executive, comparable to financial leaders at other mid-to-large cap companies in the life sciences, diagnostics, or specialized industrial sectors.
• His compensation package, including a $600,000 base salary, 80% target annual bonus, and $2 million annual equity target, along with a significant sign-on equity grant of $2.25 million, appears competitive for a Senior Vice President and CFO role at a NASDAQ-listed company of Neogen's size and market position. For example, similar roles at companies like IDEXX Laboratories (IDXX) or Zoetis (ZTS) in animal health, or Thermo Fisher Scientific (TMO) in diagnostics, would command comparable or higher compensation, reflecting the specialized expertise required.
• The structured relocation and repayment clauses are standard practice for executive hires involving significant relocation benefits, ensuring commitment from the executive.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential positive impact due to the appointment of an experienced CFO who can drive financial performance and strategic growth, potentially leading to increased shareholder value.
• Employees: The appointment of a new CFO can bring new financial strategies and operational efficiencies, potentially impacting various departments. The smooth transition plan may reduce uncertainty.
• Customers: Indirect positive impact if improved financial management leads to better product development, service, or market expansion.
• Suppliers: Indirect impact through potential changes in financial policies or supply chain management under new financial leadership.
• Creditors: A strong financial leader can enhance the company's financial stability and creditworthiness.

Next Steps

• Bryan Riggsbee to commence employment as Senior Vice President and Chief Financial Officer on November 3, 2025.
• Mr. Riggsbee to receive a one-time cash award of $250,000 by December 31, 2025.
• Mr. Riggsbee to relocate to Michigan within 24 months of service.
• David Naemura, the outgoing CFO, is expected to remain with the company until the end of the calendar year for a smooth transition.
• Neogen will continue executing its strategy to strengthen performance and deliver sustainable growth.

Key Dates

Recommendation

The appointment of Bryan Riggsbee as CFO is a positive development, bringing significant experience to Neogen's executive team. This move is expected to strengthen financial leadership and support strategic growth initiatives. However, as this filing primarily concerns a personnel change rather than immediate financial results or a major strategic shift, a "hold" recommendation is appropriate. Investors should monitor the integration of the new CFO and subsequent financial reports for tangible impacts on the company's performance before making more aggressive investment decisions. The strong background of the new CFO mitigates potential downside from a leadership transition.

Keywords

Neogen Corporation, CFO appointment, Bryan Riggsbee, Chief Financial Officer, Executive leadership, Corporate governance, Compensation package, SEC filing, NEOG, Food safety, Diagnostics, Healthcare